Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Spondyloarthropathies Clear all
Terminated Phase 3 Interventional

Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis

NCT00090129
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Onercept, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
37
States / cities
Little Rock, Arkansas • Fresno, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

NCT02404350
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Upland, California • Aurora, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 4, 2026, 9:37 AM EDT
Not listed No phase listed Observational

Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

NCT05925842
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Network
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 4, 2026, 9:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 4 Interventional Results available

Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice

NCT01147874
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
lab draws and imaging
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Dallas, Texas • Houston, Texas • Webster, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
210 mg brodalumab, 140 mg brodalumab, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Peoria, Arizona • Little Rock, Arkansas • Cypress, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

NCT03129100
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT04009499
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • San Diego, California • Palm Harbor, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 9:37 AM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 9:37 AM EDT
Not yet recruiting Phase 4 Interventional

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT07770646
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA)
Interventions
Secukinumab (IL-17i ), Upadacitinib (JAKi)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 9:37 AM EDT
Completed No phase listed Observational Results available

Psoriatic Arthritis Research Collaborative: Biologic Sub-Study

NCT03378336
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
171 participants
Timeline
2017 – 2023
U.S. locations
4
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 4 Interventional

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
ACTHar
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

NCT04936308
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
50
States / cities
Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

NCT02696798
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

NCT03158285
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 4, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

NCT05715125
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Dose A VTX958, Dose B VTX958, Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

NCT01877668
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 4, 2026, 9:37 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Novel Quantitative MRI for Axial Spondyloarthritis

NCT03778515
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Web-based Support to Manage Arthritis Pain

NCT01463189
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Interventions
painACTION: Arthritis
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Results available

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

NCT04163016
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions
Pharmacokinetics of certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

NCT00573651
View directory record Official record
Conditions
Arthritis
Interventions
Blood Draws for Serum Titers
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 4, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

NCT01695239
View directory record Official record
Conditions
Psoriasis, Arthritic
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 4, 2026, 9:37 AM EDT
Terminated No phase listed Observational

A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

NCT06715254
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 4, 2026, 9:37 AM EDT
Recruiting No phase listed Observational

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

NCT02103361
View directory record Official record
Conditions
Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease
Interventions
Ustekinumab, Guselkumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 4, 2026, 9:37 AM EDT